Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MPNST
MCID: MLG077
MIFTS: 54

Malignant Peripheral Nerve Sheath Tumor (MPNST)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

About this section

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor 12 52 58 15 17 71
Malignant Neurilemmoma 52 58 54
Neurofibrosarcoma 52 58 71
Mpnst 52 58 54
Malignant Neurofibroma 52 58
Malignant Schwannoma 52 58
Neurogenic Sarcoma 52 58
Malignant Neoplasm of the Peripheral Nerve Sheath 12
Malignant Peripheral Nerve Sheath Tumors 54

Characteristics:

Orphanet epidemiological data:

58
malignant peripheral nerve sheath tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly,Infancy; Age of death: adolescent,adult,early childhood,elderly,infantile,late childhood,young Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5940
MeSH 43 D009442
NCIt 49 C3798
SNOMED-CT 67 19897006 77418004
ICD10 via Orphanet 33 C47.9
UMLS via Orphanet 72 C0206729 C0751690
Orphanet 58 ORPHA3148
UMLS 71 C0206729 C0751690
Sources

Summaries for Malignant Peripheral Nerve Sheath Tumor

About this section
NIH Rare Diseases : 52 A malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence ), and approximately 40% chance of spreading to distant parts of the body (a metastasis ), most commonly to the lung. Treatment of MPNST begins with surgery to remove as much of the tumor as possible. Radiation therapy may be used to decrease the chance of a recurrence. Chemotherapy might be used if the whole tumor cannot be removed during surgery, or to treat a metastasis. MPNSTs are quite rare, occurring in 0.001% of the general population. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1 .

MalaCards based summary : Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to epithelioid malignant peripheral nerve sheath tumor and malignant triton tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue... more...

Sources

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

About this section

Diseases in the Benign Peripheral Nerve Sheath Tumor family:

Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 560)
# Related Disease Score Top Affiliating Genes
1 epithelioid malignant peripheral nerve sheath tumor 34.9 SOX10 S100B NF1 CD34
2 malignant triton tumor 34.7 S100B NF1 MYOG
3 neurofibromatosis, type i 34.1 PDGFRA NF1 KIT
4 neurofibrosarcoma 34.0 S100A1 NF2 NF1 KIT CD34
5 neurofibromatosis, type iv, of riccardi 33.0 PDGFRA NF2 NF1 KIT
6 rare tumor 32.1 NF2 KIT ACTC1
7 fibrosarcoma 31.7 VIM PDGFRA KIT ACTC1
8 undifferentiated pleomorphic sarcoma 31.6 PDGFRA MET KIT
9 plexiform neurofibroma 31.6 PDGFRA NF2 NF1 KIT CDKN2A CD34
10 neurilemmomatosis 31.4 NF2 NF1 CDKN2A
11 neurofibroma 31.4 VIM SOX10 S100B S100A1 PDGFRA NF2
12 perineurioma 31.3 VIM S100B S100A1 PDGFRA KIT ACTC1
13 meningioma, radiation-induced 31.3 VIM S100B NF2
14 neurilemmoma 31.2 VIM SOX10 S100B S100A1 PDGFRA NF2
15 dedifferentiated liposarcoma 31.2 MYOG MDM2 CDKN2A CDK4 ACTC1
16 cellular schwannoma 31.2 SOX10 S100A1 NF2 NF1 CD34
17 spindle cell rhabdomyosarcoma 31.2 S100B S100A1 MYOG
18 familial retinoblastoma 31.2 NF1 MDM2 CDKN2A CDK4
19 embryonal rhabdomyosarcoma 31.2 MYOG MDM2 CDK4
20 monophasic synovial sarcoma 31.2 VIM S100B CD34
21 melanoma 31.1 S100B PDGFRA MET MDM2 KIT EGFR
22 mesothelioma, malignant 31.1 VIM NF2 MET CDKN2A CDK4
23 mesenchymal cell neoplasm 31.1 PDGFRA NF1 MYOG KIT CD34
24 spindle cell sarcoma 31.1 VIM S100B NF2 MYOG MDM2 CD34
25 neuroblastoma 31.1 TOP2A NF1 MET MDM2 KIT EGFR
26 sarcoma, synovial 31.0 VIM S100B NF1 MYOG MET MDM2
27 connective tissue benign neoplasm 31.0 NF1 MDM2 KIT CDK4 CD34
28 carcinosarcoma 31.0 VIM S100A1 KIT EGFR ACTC1
29 fibrous histiocytoma 31.0 VIM S100B CD34 ACTC1
30 atypical neurofibroma 31.0 SOX10 NF1 CDKN2A CD34
31 myxofibrosarcoma 31.0 S100B MET
32 hydromyelia 31.0 VIM S100B
33 juvenile pilocytic astrocytoma 31.0 SOX10 S100B NF1 CDK4
34 granular cell tumor 31.0 VIM S100B S100A1
35 peritoneal mesothelioma 31.0 NF2 MET EGFR CDKN2A
36 leiomyosarcoma 31.0 VIM S100B S100A1 PDGFRA NF1 MYOG
37 malignant spindle cell melanoma 31.0 SOX10 NF1 KIT CD34
38 angiosarcoma 31.0 VIM MYOG MDM2 KIT CD34
39 adenocarcinoma 30.9 MET MDM2 KIT EGFR CDKN2A CDK4
40 rhabdomyosarcoma 30.9 VIM S100B PDGFRA MYOG MET MDM2
41 sarcoma 30.8 VIM S100B PDGFRA NF2 MYOG MET
42 atypical teratoid rhabdoid tumor 30.8 VIM S100B S100A1 ACTC1
43 chondrosarcoma 30.8 VIM S100B S100A1 MET MDM2 CDK4
44 amelanotic melanoma 30.8 VIM S100B KIT
45 endometrial stromal sarcoma 30.8 VIM S100B PDGFRA KIT ACTC1
46 chordoma 30.8 VIM S100B S100A1 PDGFRA MET EGFR
47 plexiform schwannoma 30.7 SOX10 NF2 NF1 KIT CD34
48 liposarcoma 30.7 VIM PDGFRA MYOG MDM2 CDKN2A CDK4
49 renal cell carcinoma, nonpapillary 30.7 VIM S100A1 PDGFRA MET KIT EGFR
50 glioma susceptibility 1 30.7 PDGFRA MDM2 EGFR CDKN2A CDK4

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:



Diseases related to Malignant Peripheral Nerve Sheath Tumor
Sources

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

About this section

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

26 (show top 50) (show all 53)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 EGFR
2 Decreased viability GR00173-A 10.16 PDGFRA
3 Decreased viability GR00221-A-1 10.16 CDKN2A EGFR KIT NF1 PDGFRA
4 Decreased viability GR00221-A-2 10.16 NF1
5 Decreased viability GR00221-A-3 10.16 CDKN2A PDGFRA
6 Decreased viability GR00221-A-4 10.16 CDKN2A EGFR NF1 PDGFRA
7 Decreased viability GR00301-A 10.16 KIT
8 Decreased viability GR00402-S-2 10.16 CDKN2A EGFR KIT NF1 PDGFRA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.05 S100B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.05 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.05 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.05 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.05 MET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.05 CDK4 SOX10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.05 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.05 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.05 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.05 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.05 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.05 MET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.05 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.05 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.05 SOX10 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.05 MET
25 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.05 MET VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.05 EGFR VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.05 MET
28 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.05 MET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.05 CDK4 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.05 EGFR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.05 VIM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.05 KIT VIM
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.05 SOX10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.05 MET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.05 CDK4 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.05 EGFR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.05 CDK4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.05 SOX10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.05 MET S100B VIM
40 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.05 SOX10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.05 SOX10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.05 CDK4
43 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.05 MET
44 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.05 SOX10
45 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.05 CDK4 EGFR KIT MET S100B SOX10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.05 KIT
47 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.05 KIT
48 Decreased substrate adherent cell growth GR00193-A-1 9.91 KIT MET
49 Decreased substrate adherent cell growth GR00193-A-2 9.91 CDK4 KIT
50 Decreased substrate adherent cell growth GR00193-A-3 9.91 CDK4 MET

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 ACTC1 CD34 CDK4 CDKN2A EGFR KIT
2 behavior/neurological MP:0005386 10.47 CDK4 CDKN2A KIT MDM2 MET MYOG
3 cellular MP:0005384 10.46 ACTC1 CD34 CDK4 CDKN2A EGFR KIT
4 cardiovascular system MP:0005385 10.44 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
5 growth/size/body region MP:0005378 10.43 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
6 embryo MP:0005380 10.41 CDK4 CDKN2A EGFR KIT MDM2 MET
7 mortality/aging MP:0010768 10.39 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
8 immune system MP:0005387 10.34 CD34 CDK4 CDKN2A EGFR KIT MDM2
9 endocrine/exocrine gland MP:0005379 10.33 CDK4 CDKN2A EGFR KIT MDM2 MET
10 integument MP:0010771 10.33 CD34 CDK4 CDKN2A EGFR KIT MDM2
11 hematopoietic system MP:0005397 10.32 CD34 CDK4 CDKN2A EGFR KIT MDM2
12 muscle MP:0005369 10.31 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
13 digestive/alimentary MP:0005381 10.3 CDK4 CDKN2A EGFR KIT MDM2 MET
14 craniofacial MP:0005382 10.26 CDK4 EGFR KIT MDM2 MET NF1
15 nervous system MP:0003631 10.23 CDK4 CDKN2A EGFR KIT MDM2 MET
16 neoplasm MP:0002006 10.22 CD34 CDK4 CDKN2A EGFR KIT MDM2
17 liver/biliary system MP:0005370 10.18 CDK4 CDKN2A EGFR KIT MDM2 MET
18 normal MP:0002873 10.18 ACTC1 CDK4 EGFR KIT MDM2 MET
19 limbs/digits/tail MP:0005371 10.08 EGFR KIT MDM2 MET NF1 PDGFRA
20 no phenotypic analysis MP:0003012 10.03 CDKN2A EGFR KIT MDM2 MET MYOG
21 pigmentation MP:0001186 9.97 CDK4 CDKN2A EGFR KIT MDM2 NF1
22 renal/urinary system MP:0005367 9.97 CDK4 EGFR KIT MDM2 MET NF1
23 reproductive system MP:0005389 9.96 CDK4 CDKN2A EGFR KIT MDM2 NF1
24 respiratory system MP:0005388 9.93 CDKN2A EGFR KIT MET MYOG NF1
25 skeleton MP:0005390 9.7 CDK4 CDKN2A EGFR HTRA1 KIT MDM2
26 vision/eye MP:0005391 9.32 CDK4 CDKN2A EGFR HTRA1 KIT MET
Sources

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

About this section

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
14
Histamine Approved, Investigational Phase 3 51-45-6 774
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16 Immunologic Factors Phase 3
17 Anti-Infective Agents Phase 3
18 Immunosuppressive Agents Phase 3
19
Isophosphamide mustard Phase 2, Phase 3 0
20 Antimitotic Agents Phase 3
21 Antirheumatic Agents Phase 3
22 Etoposide phosphate Phase 3
23 Antibiotics, Antitubercular Phase 2, Phase 3
24 Anti-Bacterial Agents Phase 2, Phase 3
25 Protein Kinase Inhibitors Phase 2, Phase 3
26 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
27 Alkylating Agents Phase 2, Phase 3
28 Topoisomerase Inhibitors Phase 2, Phase 3
29
Liposomal doxorubicin Phase 2, Phase 3 31703
30 Neurotransmitter Agents Phase 3
31 Gastrointestinal Agents Phase 3
32 Dermatologic Agents Phase 3
33 Antipruritics Phase 3
34 Histamine H1 Antagonists Phase 3
35 Serotonin Agents Phase 3
36 Histamine Antagonists Phase 3
37
Histamine Phosphate Phase 3 51-74-1 65513
38 Serotonin Antagonists Phase 3
39 Anti-Allergic Agents Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
46
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
49
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
3 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
4 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
5 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
8 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
10 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
11 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
13 An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
17 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
19 U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II Completed NCT00068367 Phase 2 erlotinib hydrochloride
20 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
21 A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
22 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
23 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
24 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
25 A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery Completed NCT01412892 Phase 2 RAD001: Everolimus
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
28 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
29 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
30 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
31 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
32 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
33 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
35 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
36 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
37 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
38 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
39 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
40 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
41 SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
42 Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
43 A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors Recruiting NCT03872427 Phase 2 Glutaminase Inhibitor CB-839 Hydrochloride
44 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults Recruiting NCT02101736 Phase 2 Cabozantinib
45 Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting NCT02390752 Phase 1, Phase 2 PLX3397
46 A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas Recruiting NCT03719430 Phase 2 Doxorubicin;APX005M
47 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
48 Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Recruiting NCT02407405 Phase 2 Selumetinib
49 A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity Recruiting NCT03962543 Phase 2 PD-0325901 oral capsule
50 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Sources

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

About this section
Sources

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

About this section

MalaCards organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

40
Lung, Bone, Breast, Thyroid, Skin, Heart, Brain
Sources

Publications for Malignant Peripheral Nerve Sheath Tumor

About this section

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 1551)
# Title Authors PMID Year
1
Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. 54 61
20399579 2010
2
The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. 54 61
20124472 2010
3
Tyrosine kinase expression in pulmonary metastases and paired primary tumors. 54 61
19948538 2010
4
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. 54 61
19634141 2010
5
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. 54 61
19921253 2009
6
Malignant peripheral nerve sheath tumor of the uterine cervix expressing both S-100 protein and HMB-45. 54 61
20025639 2009
7
Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. 54 61
19306381 2009
8
Expression and significance of EGFR in malignant peripheral nerve sheath tumor. 54 61
19330289 2009
9
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. 54 61
18281533 2008
10
Malignant peripheral nerve sheath tumor of the breast: case report. 54 61
18154670 2007
11
Primary pulmonary malignant peripheral nerve sheath tumor: a case report. 54 61
17910355 2007
12
Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. 54 61
17558420 2007
13
Low grade malignant peripheral nerve sheath tumor with smooth muscle differentiation. 54 61
17119986 2007
14
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. 54 61
17235305 2007
15
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 54 61
17300669 2007
16
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. 54 61
16528378 2006
17
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. 54 61
16510576 2006
18
Calretinin expression in tumors of adipose tissue. 54 61
16613326 2006
19
Malignant peripheral nerve sheath tumor arising from the colon in a newborn: report of a case and review of the literatures. 54 61
16481232 2006
20
ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. 54 61
15609299 2005
21
[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. 54 61
15774214 2005
22
CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. 54 61
14730703 2004
23
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. 54 61
14673046 2003
24
Protein gene product 9.5 (PGP 9.5) is not a specific marker of neural and nerve sheath tumors: an immunohistochemical study of 95 mesenchymal neoplasms. 54 61
14559978 2003
25
Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. 54 61
14508395 2003
26
p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. 54 61
14519636 2003
27
Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. 54 61
12838503 2003
28
Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. 54 61
12730955 2003
29
Immunohistochemical demonstration of EMA/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors. 54 61
12692193 2003
30
Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. 54 61
12152785 2002
31
Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. 54 61
11865845 2002
32
Malignant melanoma with a myxoid stroma: a diagnostic pitfall on fine-needle aspiration biopsy. 54 61
11536443 2001
33
Soft tissue sarcomas in the African hedgehog (Atelerix albiventris): microscopic and immunohistologic study of three cases. 54 61
11580072 2001
34
Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. 54 61
11688574 2001
35
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. 54 61
11438454 2001
36
Expanding the spectrum of malignant change in schwannomas: epithelioid malignant change, epithelioid malignant peripheral nerve sheath tumor, and epithelioid angiosarcoma: a study of 17 cases. 54 61
11145248 2001
37
Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. 54 61
11145252 2001
38
Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. 54 61
10791998 2000
39
Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases. 54 61
10584703 1999
40
Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. 54 61
10549251 1999
41
Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. 54 61
10469433 1999
42
CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene. 54 61
9354454 1997
43
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. 61
31594823 2020
44
Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. 61
31163235 2020
45
Sellar surprises: a single-centre experience of unusual sellar masses. 61
31910151 2020
46
Malignant peripheral nerve sheath tumor in the nasopharynx and oropharynx: a case report. 61
31937162 2020
47
Identification of a novel fusion transcript EWSR1-VEZF1 by anchored multiplex PCR in malignant peripheral nerve sheath tumor. 61
31812440 2020
48
Giant Malignant Peripheral Nerve Sheath Tumor of the Head and Neck: A Case Report and Literature Review. 61
31914814 2020
49
Intraoperative Surgical Margin Clearance - Correlation of Touch Imprint Cytology, Frozen Section Diagnosis, and Histopathological Diagnosis. 61
32002379 2020
50
Soft tissue sarcoma in neurofibromatosis type 1: A rare case of malignant peripheral nerve sheath tumor of the skin. 61
31964130 2020
Sources

Variations for Malignant Peripheral Nerve Sheath Tumor

About this section

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

7 (show all 45)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17387 1 142600000 147000000 Gain Malignant peripheral nerve sheath tumor
2 22132 1 165500000 170900000 Gain Malignant peripheral nerve sheath tumor
3 23047 1 170900000 176000000 Gain Malignant peripheral nerve sheath tumor
4 49109 11 102900000 112500000 Loss Malignant peripheral nerve sheath tumor
5 49995 11 112500000 121200000 Loss Malignant peripheral nerve sheath tumor
6 53584 11 31000000 36400000 Loss Malignant peripheral nerve sheath tumor
7 61507 12 1 3100000 Gain FOXM1 Malignant peripheral nerve sheath tumor
8 65742 12 21200000 26300000 Amplification SOX5 Malignant peripheral nerve sheath tumor
9 66816 12 3300000 10100000 Gain Malignant peripheral nerve sheath tumor
10 67235 12 38200000 49100000 Gain Malignant peripheral nerve sheath tumor
11 69080 12 5300000 10000000 Gain NOL1 Malignant peripheral nerve sheath tumor
12 69882 12 56428269 56432431 Gain CDK4 Malignant peripheral nerve sheath tumor
13 69960 12 56600000 71500000 Gain Malignant peripheral nerve sheath tumor
14 71535 12 71500000 86700000 Gain Malignant peripheral nerve sheath tumor
15 73254 12 92600000 109000000 Gain Malignant peripheral nerve sheath tumor
16 73259 12 92600000 96200000 Gain Malignant peripheral nerve sheath tumor
17 75380 13 19500000 25500000 Gain Malignant peripheral nerve sheath tumor
18 76637 13 34000000 55300000 Gain Malignant peripheral nerve sheath tumor
19 79536 13 73300000 77200000 Gain Malignant peripheral nerve sheath tumor
20 85488 14 47200000 67900000 Loss Malignant peripheral nerve sheath tumor
21 87451 14 73800000 107349540 Gain Malignant peripheral nerve sheath tumor
22 97234 16 1 10500000 Gain Malignant peripheral nerve sheath tumor
23 102841 16 57400000 90354753 Gain Malignant peripheral nerve sheath tumor
24 105377 16 7900000 14800000 Gain Malignant peripheral nerve sheath tumor
25 115613 17 58300000 81195210 Gain Malignant peripheral nerve sheath tumor
26 124065 19 1 13900000 Gain Malignant peripheral nerve sheath tumor
27 147242 2 61300000 68600000 Gain Malignant peripheral nerve sheath tumor
28 150135 2 96800000 114400000 Gain Malignant peripheral nerve sheath tumor
29 163892 22 32200000 44200000 Gain Malignant peripheral nerve sheath tumor
30 172609 3 184500000 198022430 Gain Malignant peripheral nerve sheath tumor
31 174546 3 2800000 16400000 Gain Malignant peripheral nerve sheath tumor
32 175421 3 39400000 54400000 Gain Malignant peripheral nerve sheath tumor
33 196162 5 159900000 180915260 Gain Malignant peripheral nerve sheath tumor
34 198008 5 18400000 23300000 Gain Malignant peripheral nerve sheath tumor
35 209673 6 27000000 57000000 Gain Malignant peripheral nerve sheath tumor
36 213890 6 52900000 70000000 Gain Malignant peripheral nerve sheath tumor
37 220382 7 13800000 43300000 Gain Malignant peripheral nerve sheath tumor
38 227906 7 72200000 86400000 Gain Malignant peripheral nerve sheath tumor
39 240607 8 52600000 146364022 Gain Malignant peripheral nerve sheath tumor
40 241476 8 6200000 36500000 Gain Malignant peripheral nerve sheath tumor
41 244863 9 1 14200000 Gain Malignant peripheral nerve sheath tumor
42 247559 9 130300000 135900000 Gain Malignant peripheral nerve sheath tumor
43 249423 9 14200000 28000000 Loss Malignant peripheral nerve sheath tumor
44 255080 9 72339785 73251640 Dramatically overexpressed,genomicallyamplified TRPM3 Malignant peripheral nerve sheath tumor
45 255774 9 84100000 102600000 Gain Malignant peripheral nerve sheath tumor
Sources

Expression for Malignant Peripheral Nerve Sheath Tumor

About this section
Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.
Sources

Pathways for Malignant Peripheral Nerve Sheath Tumor

About this section

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14 VIM S100B S100A1 PDGFRA NRG1 NF1
2
ERK Signaling 63
Show member pathways
 13.69 VIM SOX10 PDGFRA NRG1 NF1 MET
3
Developmental Biology 65
Show member pathways
 13.44 PDGFRA NRG1 NF1 MYOG MET KIT
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.31 VIM PDGFRA NRG1 NF1 MET KIT
5
GAB1 signalosome 65
Show member pathways
 13.07 PDGFRA NRG1 MET MDM2 KIT EGFR
6
Phospholipase-C Pathway 63
Show member pathways
 13 PDGFRA NRG1 MET MDM2 KIT EGFR
7
PI3K-Akt signaling pathway 36
Show member pathways
 12.92 PDGFRA MET MDM2 KIT EGFR CDK4
8
Endometrial cancer 36
Show member pathways
 12.81 PDGFRA MDM2 KIT EGFR CDKN2A CDK4
9
MAPK signaling pathway 36 1
12.71 PDGFRA NF1 MET KIT EGFR
10
Gastric cancer 36
Show member pathways
 12.7 MET KIT EGFR CDKN2A CDK4
11
Ras signaling pathway 36
Show member pathways
 12.67 PDGFRA NF1 MET KIT EGFR
12
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.63 PDGFRA NRG1 MET MDM2 KIT EGFR
13
Pathways in cancer 36
12.59 PDGFRA MET MDM2 KIT EGFR CDKN2A
14
ErbB signaling pathway 1 36
Show member pathways
 12.47 PDGFRA NRG1 NF1 MET MDM2 EGFR
15
DNA Damage 4
12.42 VIM TOP2A MDM2 CDKN2A CDK4
16
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.35 PDGFRA NRG1 MET KIT EGFR
17
MicroRNAs in cancer 36
12.34 VIM PDGFRA MET MDM2 EGFR CDKN2A
18
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.2 PDGFRA NRG1 MET KIT EGFR
19
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.14 PDGFRA MET MDM2 EGFR CDK4
20
Glioma 36
Show member pathways
 12.1 PDGFRA NF1 MET MDM2 EGFR CDKN2A
21
Integrated Breast Cancer Pathway 1
12.09 NF1 MDM2 EGFR CDK4
22
Signaling by PTK6 65
Show member pathways
 11.98 NRG1 NF1 EGFR CDK4
23
Signaling by ERBB4 65
Show member pathways
 11.86 S100B NRG1 MDM2 EGFR
24
Tyrosine Kinases / Adaptors 4
11.82 PDGFRA NRG1 MET KIT EGFR
25
Retinoblastoma (RB) in Cancer 1
11.78 TOP2A MDM2 CDK4
26
Platinum drug resistance 36
11.69 TOP2A MDM2 CDKN2A
27
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.69 VIM SOX10 S100B PDGFRA
28
Bladder cancer 36 1
11.62 MDM2 EGFR CDKN2A CDK4
29
Central carbon metabolism in cancer 36
11.54 PDGFRA MET KIT EGFR
30
ATF-2 transcription factor network 1
11.53 PDGFRA NF1 CDK4
31
Photodynamic therapy-induced AP-1 survival signaling. 1
11.49 PDGFRA EGFR CDKN2A
32
Oncogene Induced Senescence 65
11.22 MDM2 CDKN2A CDK4
33
Glioblastoma Multiforme 63
11.21 PDGFRA NF2 NF1 MDM2 EGFR CDKN2A
34
Cardiac Progenitor Differentiation 1
11.18 PDGFRA NRG1 KIT ACTC1
35
G-protein signaling_Rap2B regulation pathway 22
10.96 VIM PDGFRA NRG1 MET KIT EGFR
Sources

GO Terms for Malignant Peripheral Nerve Sheath Tumor

About this section

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.63 TOP2A S100A1 PDGFRA MDM2 EGFR CDK4
2 cytoplasm GO:0005737 9.58 VIM TOP2A SOX10 SH3PXD2A S100B S100A1
3 receptor complex GO:0043235 9.56 PDGFRA MET KIT EGFR
4 basal plasma membrane GO:0009925 9.13 MET EGFR CD34

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10 PDGFRA MET KIT EGFR CDKN2A CDK4
2 positive regulation of apoptotic process GO:0043065 9.89 TOP2A S100B NF1 CDKN2A CDK4
3 peptidyl-tyrosine phosphorylation GO:0018108 9.78 PDGFRA MET KIT EGFR
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 PDGFRA MET KIT EGFR
5 liver development GO:0001889 9.75 NF1 MET EGFR
6 negative regulation of protein kinase activity GO:0006469 9.74 NF2 NF1 CDKN2A
7 cellular response to growth factor stimulus GO:0071363 9.72 MYOG MDM2 EGFR
8 regulation of cell proliferation GO:0042127 9.72 NF2 NF1 KIT EGFR CDK4
9 hematopoietic progenitor cell differentiation GO:0002244 9.71 TOP2A PDGFRA KIT
10 wound healing GO:0042060 9.71 PDGFRA NRG1 NF1 EGFR
11 positive regulation of cell proliferation GO:0008284 9.7 S100B PDGFRA NRG1 MDM2 KIT EGFR
12 positive regulation of fibroblast proliferation GO:0048146 9.69 PDGFRA EGFR CDK4
13 positive regulation of protein kinase B signaling GO:0051897 9.65 PDGFRA NRG1 MET KIT EGFR
14 peripheral nervous system development GO:0007422 9.61 SOX10 NRG1 NF1
15 amyloid fibril formation GO:1990000 9.59 MDM2 CDKN2A
16 tongue development GO:0043586 9.58 KIT EGFR
17 somatic stem cell division GO:0048103 9.56 KIT CDKN2A
18 negative regulation of cell-matrix adhesion GO:0001953 9.54 NF2 NF1 CDKN2A
19 MAPK cascade GO:0000165 9.43 PDGFRA NRG1 NF1 MET KIT EGFR
20 positive regulation of gene expression GO:0010628 9.23 VIM SOX10 NRG1 MDM2 KIT CDKN2A

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 PDGFRA MET KIT EGFR CDKN2A CDK4
2 nucleotide binding GO:0000166 9.72 PDGFRA MET KIT EGFR CDK4
3 identical protein binding GO:0042802 9.56 VIM SOX10 S100B S100A1 MET MDM2
4 protein tyrosine kinase activity GO:0004713 9.46 PDGFRA MET KIT EGFR
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 PDGFRA MET KIT EGFR
Sources

Sources for Malignant Peripheral Nerve Sheath Tumor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....